03.10.2012 - Clinical data presented at a Congress in Vienna shows that a new Pharmamar drug could step up to the success of its paragon Yondelis.
Pharmamar S.A. from Colmenar Viejo is part of Spain’s largest biotech Zeltia S.A. It is known for its marine tunicate-derived anti-cancer drug Yondelis. But there is another potentially marketable drug named PM01183 (lurbinectedin) in the pipeline. On 30 September, new clinical data was presented at the 37th Congress of the European Society of Molecular Oncology (ESMO) in Vienna. Results from the first part of a two-stage Phase II study in patients with platinum-resistant or refractory ovarian cancers were well-perceived, where a confirmed response to the treatment was observed in 6 out of 22 patients. Moreover, the disease had only progressed in 6 patients at the first evaluation, which means that the tumour remained stable in the remaining 10 patients (disease control rate: 73%). The drug showed no toxicity-related problems. The second stage was launched in April with the enrolment of 60 additional patients, who will be randomised to either the PM01183 arm or the active comparator arm where GSK’s topotecan is given.
Other indications where PM01183’s potential is scrutinised include non-small-cell lung carcinoma and breast cancer. Data of a Phase Ib study also presented at the meeting suggest that a combination of PM01183 with the nucleoside analogue gemcitabine improves the anti-tumour activities in the first mentioned indication when compared to treatments with each drug alone. The latter indication is dealt with in a Phase II study with metastatic breast cancer (MBC) patients which started in June this year. Here, patients are stratified into one group where the women have certain deleterious germline mutations in BRCA1/2 and another with woman without such mutations. Pharmamar wants to show that PM01183 works for BRCA 1/2-associated MBCs.
Pharmamar also tries to widen the scope of Yondelis, the first cancer medication ever to be developed in Spain. Moving from 2nd line to 1st line indications Yondelis (trabectedin) is currently under investigation for its strength to fight non-operable and/or metastatic soft tissue sarcomas. In the trial named GEIS-20 standard doxorubicin treatment is compared against a doxorubicin-trabectedin-combination. Results of the Phase II, open label, randomised study with 182 patients are expected in Q4/12.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more